Equity Profile

PAHC

Phibro Animal Health Corporation

Health CarePharmaceuticals$1.3B

May6Wed

Post-Earnings Recap

ReportedQ3-2026After Close4:30 PM EDT

Phibro Animal Health Corporation Beats on EPS, Stock Up 4.02%

Metric	Actual	Expected	Surprise
EPS	$0.76	$0.71	+5.85%
Revenue	N/A	$367M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Phibro Animal Health Corporation Beats on EPS, Stock Up 4.02%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.76	$0.71	+5.85%
Revenue	N/A	$367M	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Phibro Animal Health Corporation reported better-than-expected earnings per share, which contributed to a positive stock reaction, with shares rising by 4.02%. However, the company did not provide revenue figures or any forward guidance, leaving some uncertainty about future performance. Investors may be encouraged by the EPS beat, but the lack of revenue data could lead to cautious sentiment moving forward.

Company Snapshot

Phibro Animal Health Corporation (PAHC) operates in the health care sector, focusing on pharmaceuticals for animal health. The company develops and markets products for livestock and companion animals, which is crucial as global demand for animal protein continues to rise.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$0.71

Revenue

Revenue figures will indicate the overall sales performance and market demand for Phibro's products.

$367M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+23.89%

Avg Stock Reaction

+0.37%

Last Quarter Recap

In Q2-2026, Phibro reported an EPS of $0.87, significantly exceeding the estimate of $0.69, marking a 27% surprise. However, the stock fell 0.75% the following day, indicating market caution despite the strong earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Phibro to continue its positive earnings trend with an EPS of $0.71 and revenue of $367M. There is cautious optimism given the company's recent performance.

Bull Case

If Phibro beats expectations again, it could signal strong operational efficiency and continued demand for its products, potentially boosting investor confidence.

Bear Case

Conversely, if the company fails to meet earnings expectations, it could raise concerns about market demand and operational challenges, leading to a negative reaction.

Key Metrics to Watch

EPS

$0.71

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$367M

Revenue figures will indicate the overall sales performance and market demand for Phibro's products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Phibro's revenue meet or exceed the consensus estimate of $367M?

Revenue performance is critical to gauge the company's market position and demand for its products.

How will management address the recent stock price declines despite positive earnings surprises?

Investor sentiment may hinge on management's commentary about future growth and market challenges.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Phibro to exceed revenue expectations due to strong demand in the animal health market, which could be bolstered by recent industry trends.

Supporting Evidence

Phibro has consistently beaten EPS estimates, suggesting stronger operational performance than anticipated.

The options market is pricing in a larger move than historical averages, indicating heightened investor expectations.

Insider selling could indicate a strategic shift rather than a lack of confidence in the company's future.

Key Risk

If revenue comes in below $357M, it could undermine the bullish sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Phibro can sustain its recent earnings momentum amid potential market pressures.

Bull Confirmed If

An EPS of $0.73 or higher would confirm strong operational performance and support the bull case.

Bear Confirmed If

An EPS below $0.70 would raise concerns about demand and operational efficiency.

Pre-Earnings Positioning

Options Market

Implied Move

±17.72%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±16.5% while PAHC has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

46.5%

Calls (10K)P/C Ratio: 1.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$2.4M

42,240 sh

1 insider

Net

$2.4M

Net selling

Most Active Insiders· 12 open-market trades

President and CEOBENDHEIM JACK
$2.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Phibro beats estimates, history suggests the stock could rise by around 0.17%, confirming strong operational efficiency.

In-Line / Cautious

An in-line report could lead to a muted reaction as investors await clearer guidance from management.

Miss

If the company misses expectations, history suggests a potential decline of around 1.56%, raising concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product demand trends in the animal health market.
2Management's outlook on pricing strategies and cost management.
3Insights into competitive pressures and how Phibro plans to address them.
4Details on any new product launches or pipeline developments.
5Clarification on the reasons behind recent insider selling.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$0.71

Revenue

Revenue figures will indicate the overall sales performance and market demand for Phibro's products.

$367M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+23.89%

Avg Stock Reaction

+0.37%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Phibro to continue its positive earnings trend with an EPS of $0.71 and revenue of $367M. There is cautious optimism given the company's recent performance.

Bull Case

If Phibro beats expectations again, it could signal strong operational efficiency and continued demand for its products, potentially boosting investor confidence.

Bear Case

Conversely, if the company fails to meet earnings expectations, it could raise concerns about market demand and operational challenges, leading to a negative reaction.

Key Metrics to Watch

EPS

$0.71

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$367M

Revenue figures will indicate the overall sales performance and market demand for Phibro's products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Phibro's revenue meet or exceed the consensus estimate of $367M?

Revenue performance is critical to gauge the company's market position and demand for its products.

How will management address the recent stock price declines despite positive earnings surprises?

Investor sentiment may hinge on management's commentary about future growth and market challenges.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Phibro to exceed revenue expectations due to strong demand in the animal health market, which could be bolstered by recent industry trends.

Supporting Evidence

Phibro has consistently beaten EPS estimates, suggesting stronger operational performance than anticipated.

The options market is pricing in a larger move than historical averages, indicating heightened investor expectations.

Insider selling could indicate a strategic shift rather than a lack of confidence in the company's future.

Key Risk

If revenue comes in below $357M, it could undermine the bullish sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Phibro can sustain its recent earnings momentum amid potential market pressures.

Bull Confirmed If

An EPS of $0.73 or higher would confirm strong operational performance and support the bull case.

Bear Confirmed If

An EPS below $0.70 would raise concerns about demand and operational efficiency.

Pre-Earnings Positioning

Options Market

Implied Move

±17.72%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±16.5% while PAHC has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

46.5%

Calls (10K)P/C Ratio: 1.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$2.4M

42,240 sh

1 insider

Net

$2.4M

Net selling

Most Active Insiders· 12 open-market trades

President and CEOBENDHEIM JACK
$2.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Phibro beats estimates, history suggests the stock could rise by around 0.17%, confirming strong operational efficiency.

In-Line / Cautious

An in-line report could lead to a muted reaction as investors await clearer guidance from management.

Miss

If the company misses expectations, history suggests a potential decline of around 1.56%, raising concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product demand trends in the animal health market.
2Management's outlook on pricing strategies and cost management.
3Insights into competitive pressures and how Phibro plans to address them.
4Details on any new product launches or pipeline developments.
5Clarification on the reasons behind recent insider selling.